



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		<b>Application Number</b>	10/053,753		
		<b>Filing Date</b>	January 22, 2002		
		<b>First Named Inventor</b>	Lester F. Lau		
		<b>Group Art Unit</b>	1632		
		<b>Examiner Name</b>	To be assigned		
<b>Sheet</b>	1	<b>of</b>	5	<b>Attorney Docket Number</b>	214448-00017

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
[Signature]	A1	US-5,408,040	04-18-1995	Grotendorst <i>et al.</i>	
	A2	US-4,554,101	11-19-1985	Hopp	
	A3	US-5,945,300	08-31-1999	Li <i>et al.</i>	
	A4	US-6,008,022	12-28-1999	Su <i>et al.</i>	
	A5	US-6,149,916	11-21-2000	Grotendorst <i>et al.</i>	
	A6	US-6,150,101	11-21-2000	Grotendorst <i>et al.</i>	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
[Signature]	B1	EP 0 495 674	07-22-1992	Purchio <i>et al.</i>		
	B2	WO 96/01896	01-25-1996	Li <i>et al.</i>		
	B3	WO 97/33995 A	09-18-1997	Lau		
	B4	AU 733382 B2	05-10-2001	Lau		
	B5	AU 2329697 A	10-01-1997	Lau		
	B6	CA 2248549N A1	09-18-1997	Lau		
	B7	EP 0888452 A2	01-07-1999	Lau		
	B8	JP 2000506732 T	06-06-2000	Lau		
	B9	WO 9733995 A2	09-18-1997	Lau		

<b>Examiner Signature</b>	[Signature]	<b>Date Considered</b>	10/30/04
---------------------------	-------------	------------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds codes of USPTO Patent Documents as [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		<b>Application Number</b>	10/053,753		
		<b>Filing Date</b>	January 22, 2002		
		<b>First Named Inventor</b>	Lester F. Lau		
		<b>Group Art Unit</b>	1632		
		<b>Examiner Name</b>	To be assigned		
<b>Sheet</b>	2	<b>of</b>	5	<b>Attorney Docket Number</b>	214448-00017


<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
762	C1	O'Brian et al. Molecular and Cellular Biology 10(7):3569-77, Jul. 1990.	
762	C2	G.D. Phillips et al., Natl. Library of Medicine, "Vascular endothelial growth factor(rhVEGF165) stimulates direct angiogenesis in the rabbit cornea," in vivo Nov.-Dec. 1994,8(6):abstract.	
	C3	T.Kanoh et al., Natl. Library of Medicine, "Suppression of in vivo tumor-induced angiogenesis by the protein-bound polysaccharide PSK," in vivo Mar.-Apr. 1994, 8(2):abstract.	
	C4	G.D. Phillips et al., Natl. Library of Medicine, "Platelet derived wound healing factors (PDWHF) accelerate and augment wound healing angiogenesis in the rat," in vivo Mar.-Apr. 1994,8(2):abstract.	
	C5	D.S.Grant et al., Annals New York Academy of Sciences, "Role of Basement Membranes in Vascular Development," (1990),588:61-72.	
	C6	A.E.Canfield et al., Journal of Cell science, "Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells," Feb. 1995, 108,pp. 797-809.	
	C7	M.L. Kireeva et al., Molecular and Cellular Biology, "Cyr61, a Product of a growth Factor-Inducible immediate-early gene, promotes cell proliferation, migration, and adhesion," Apr. 1996, vol. 16, No. 4, pp. 1326-1334.	
	C8	A.M. Babic et al., Proc. Natl.Acad.Sci. USA, "Cyr61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth," May 1998, vol. 95, pp. 6355-6360.	
	C9	J.U. Bowie et al., Science, "Deciphering the message in protein sequences:tolerance to amino acid substitutions," Mar. 1990, vol. 247, pp. 1306-1310.	
	C10	J.T. Ngo et al., Protein Folding Problem and Teriay Structure Prediction, "Computational complexity, protein structure prediction, and the levinthal paradox," 14:491-495.	
	C11	J.A. Parsons, Natl.Institute for Medical Research, "Peptide Hormones," Jun. 1976, pp. 5-7.	

<b>Examiner Signature</b>	<i>Joe W. [Signature]</i>	<b>Date Considered</b>	10/30/04
---------------------------	---------------------------	------------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for Form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		<b>Application Number</b>	10/053,753		
		<b>Filing Date</b>	January 22, 2002		
		<b>First Named Inventor</b>	Lester F. Lau		
		<b>Group Art Unit</b>	1632		
		<b>Examiner Name</b>	To be assigned		
<b>Sheet</b>	3	<b>of</b>	5	<b>Attorney Docket Number</b>	214448-00017

C12	Adra, C.N. et al., "Cloning and expression of the mouse pgk-1 gene and the nucleotide sequence of its promoter," Gene, 60:65-74 (1987).
C13	Ahrens, P.B. et al., "Stage-Related Capacity for Limb Chondrogenesis in Cell Culture," Developmental Biology, 60:69-82 (1977).
C14	Bradham, D.M. et al., "Connective Tissue Growth Factor: a Cysteine-rich Mitogen Secreted by Human Vascular Endothelial Cells Is Related to the SRC-induced Immediate Early Gene Product CEF-10," Journal Cellular Biology, 114(6):1285-1294 (Sep., 1991).
C15	Fajardo, L.F. et al., "Methods in Laboratory Investigation: The Disc Angiogenesis System," Laboratory Investigation, 58(6):718-724 (1988).
C16	Greenberger, J.S. et al., "Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines," Proc. Natl. Acad. Sci. (USA), 80:2931-2935 (May, 1983).
C17	Hartzell, S. et al., "A Growth Factor-Responsive Gene of Murine BALB/c 3T3 Cells Encodes a Protein Homologous to Human Tissue Factor," Molecular and Cellular Biology, 9(6):2567-2573 (Jun., 1989).
C18	Joliot, V. et al., "Proviral Rearrangements and Overexpression of a New Cellular Gene (nov) in Myeloblastosis-Associated Virus Type 1-Induced Nephroblastomas," Molecular and Cellular Biology, 12(1):10-21 (Jan., 1992).
C19	Latinkic, B.V. et al., "Promoter function and structure of the growth factor-inducible immediate early gene <i>cyr61</i> ," Nucleic Acids Research, 19(12):3261-3267 (1991).
C20	Lau, L.F. et al., "Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells," EMBO Journal, 4(12):3145-3151 (1985).
C21	Lau, L.F. "Growth factors and growth control," Current Opinion in Cell Biology, 2:280-284 (1990).
C22	Lau, L.F. et al., "Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: Coordinate regulation with <i>c-fos</i> or <i>c-myc</i> ," Proc. Natl. Acad. Sci. (USA), 84:1182-1186 (Mar., 1987).
C23	Lau, L.F. et al., "Genes induced by serum growth factors," in Molecular Aspects of Cellular Regulation, vol. 6: The hormonal control regulation of gene transcription, Chapter 13, Cohen, P. et al., (eds.), Elsevier Science Publishers B.V., Amsterdam, pp. 257-293 (1991).

<b>Examiner Signature</b>	<i>Joe Winters</i>	<b>Date Considered</b>	10/30/02
---------------------------	--------------------	------------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAY 12 2003

TECH CENTER 160012990



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b>	10/053,753
		<b>Filing Date</b>	January 22, 2003
		<b>First Named Inventor</b>	Lester F. Lau
		<b>Group Art Unit</b>	1632
		<b>Examiner Name</b>	To be assigned
		<b>Attorney Docket Number</b>	214448-00017
Sheet	4	of	5

76	C24	O'Brien, T.P. et al., "Expression of <i>cyr61</i> , a Growth Factor-Inducible Immediate-Early Gene," <i>Molecular and Cellular Biology</i> , 10(7):3569-3577 (Jul., 1990).	
	C25	O'Brien, T.P. et al., "Expression of the Growth Factor-inducible Immediate Early Gene <i>cyr61</i> Correlates with Chondrogenesis during Mouse Embryonic Development," <i>Cell Growth &amp; Differentiation</i> , 3:645-654 (Sep., 1992).	
	C26	Ryseck, R-P. et al., "Structure, Mapping, and Expression of <i>fisp-12</i> , a Growth Factor-inducible Gene Encoding a Secreted Cysteine-rich Protein," <i>Cell Growth and Differentiation</i> , 2:225-233 (May, 1991).	
	C27	Spooner, E. et al., "Continuous in vitro generation of multipotential stem cell clones from src-infected cultures," <i>Nature</i> , 310:288-230 (Jul., 1984).	
	C28	Tolsma, S.S. et al., "Peptides Derived from Two Separated Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity," <i>Journal of Cell Biology</i> , 122(2):497-511 (Jul., 1993).	
	C29	Yang, G.P. et al., "Cyr61, Product of a Growth Factor-inducible Immediate Early Gene, Is Associated with Extracellular Matrix and the Cell Surface," <i>Cell Growth and Differentiation</i> , 2:351-357 (Jul., 1991).	
	C30	Yang, G.P., "Biochemical and Functional Analysis of Cyr61, The Product of a Growth Factor-Inducible Immediate Early Gene," Ph.D. Thesis, University of Illinois at Chicago, Chicago, Illinois (1993).	
	C31	Iwamoto et al., <i>Advances in Experimental Medicine and Biology</i> , 324:141-149 (1992).	
	C32	Yang, G.P. <i>Dissertation Abstracts International</i> , 54(8):DA9335171, February, (1994).	
	C33	O'Brien et al. <i>Cell Growth and Differentiation</i> 3:645-354, (1992).	
	C34	Bork, P. <i>FEBS letters</i> 327(2):125-130, July, (1993).	
	C35	Lin et al. <i>Cancer Research</i> 53:2950-2953, July, (1993).	
	C36	Felch et al., <i>Regional Immunology</i> 4:363-370, (1992).	
	C37	Mackinnon et al., <i>Invasion Metastasis</i> 12:241-252 (1992).	
	C38	Wallukar, G. et al. <i>Z. Kardiol.</i> , 81:Suppl. 4, 79-83 (1992).	
	C39	Hoermann, et al. <i>Acta Endocrinologica</i> 111:487-493 (1986).	


<b>Examiner Signature</b>	<i>Joe Winters</i>	<b>Date Considered</b>	10/30/01
---------------------------	--------------------	------------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
MAY 12 2003  
TECH CENTER 160012900



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		<b>Application Number</b>	10/053,753		
		<b>Filing Date</b>	January 22, 2002		
		<b>First Named Inventor</b>	Lester F. Lau		
		<b>Group Art Unit</b>	1632		
		<b>Examiner Name</b>	To be assigned		
<b>Sheet</b>	5	<b>of</b>	5	<b>Attorney Docket Number</b>	214448-00017

7w	C40	Jedsadayanmata et al. "Activation-dependent adhesion of human platelets to Cyr 61 and Fisp12/Mouse Connective Tissue Growth Factor is Mediated Through Integrin Alpha IIB beta3," Journal of Biol. Chem. 274 (34):24321-24327 (1999).	
7w	C41	Chen N. et al. "Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin alpha6beta1 and cell surface heparin sulfate proteoglycans," Journal of Bio. Chem. 275 (32):24953-24961 (2000).	

<b>Examiner Signature</b>	<i>Joel Fuller</i>	<b>Date Considered</b>	10/30/04
-------------------------------	--------------------	----------------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Go 1632  
#6  
5/12/03

PATENT  
Attorney Docket No. 214448-00017

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Lester F. Lau *et al.*

Application No.: 10/053,753

Filing Date: January 22, 2002

Title: Extracellular matrix  
signaling molecules

Group Art Unit: 1632

Examiner: To Be Assigned

**CERTIFICATE OF MAILING**

I hereby certify that this paper is being deposited  
with the United States Postal Service as first class  
mail in an envelope addressed to: Assistant  
Commissioner for Patents, Washington, D.C. 20231,  
on this date.

05/05/03  
Date

Teddy C. Scott, Jr., Ph.D.  
Registration No. 23,573

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

**RECEIVED**

MAY 12 2003

Assistant Commissioner for Patents  
Washington, D.C. 20231

**TECH CENTER 1600/2900**

Dear Sir:

In accordance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, the applicant calls to the attention of the examiner references listed on the attached Forms PTO/SB/08A and PTO/SB/08B (the "Forms").

The above-referenced application is a continuation of U.S. Application No. 09/142,569, which issued as U.S. Patent No. 6,413,735. All the references listed on the Forms, except for references C38 and C39, were submitted on an information disclosure statement in U.S. Application No. 09/142,569. Pursuant to 37 C.F.R. § 1.98(d), we submit herewith copies of references C38 and C39.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes art under 35 U.S.C. §102 or §103.


U.S. Appln. No. 10/053,753  
Filed: January 22, 2002

Docket No. 214448-00017

The Information Disclosure Statement is submitted before receipt of the First Office Action on the merits. Consequently, pursuant to 37 C.F.R. § 1.97(b), no fee is believed to be due with this submission. However, should any fees be deemed necessary in connection with the filing of this Information Disclosure Statement, the Assistant Commissioner is hereby authorized to deduct any such fees from our Deposit Account No. 50-1214.

Respectfully submitted,

KATTEN MUCHIN ZAVIS ROSENMAN

By:   
Teddy C. Scott, Jr., Ph.D.  
Registration No.: 53,573

Dated: May 5, 2003  
KATTEN MUCHIN ZAVIS ROSENMAN  
525 W. Monroe Street, Suite 1600  
Chicago, IL 60661  
(312) 902-5321 (Telephone)  
(312) 577-4708 (FAX)